Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2017, Article ID 4693417, 8 pages
https://doi.org/10.1155/2017/4693417
Research Article

Radiolabeling and Quantitative In Vivo SPECT/CT Imaging Study of Liposomes Using the Novel Iminothiolane-99mTc-Tricarbonyl Complex

1Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest 1117, Hungary
2Department of Biophysics and Radiation Biology, Semmelweis University, Budapest 1094, Hungary
3Institute of Nuclear Techniques, Budapest University of Technology and Economics, Budapest 1111, Hungary
4CROmed Translational Research Centers, Budapest 1047, Hungary

Correspondence should be addressed to Zoltán Varga; uh.atm.ktt@natloz.agrav

Received 17 March 2017; Accepted 4 May 2017; Published 31 May 2017

Academic Editor: Ralf Schirrmacher

Copyright © 2017 Zoltán Varga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Barenholz, “Doxil®: the first FDA-approved nano-drug: lessons learned,” Journal of Controlled Release, vol. 160, no. 2, pp. 117–134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. T. M. Allen and P. R. Cullis, “Drug delivery systems: entering the mainstream,” Science, vol. 303, no. 5665, pp. 1818–1822, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. A. D. Bangham, “Liposomes: the Babraham connection,” Chemistry and Physics of Lipids, vol. 64, no. 1–3, pp. 275–285, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. T. M. Allen, “Liposomal drug formulations: rationale for development and what we can expect for the future,” Drugs, vol. 56, no. 5, pp. 747–756, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. H. I. Chang and M. Yeh, “Clinical development of liposome based drugs: formulation, characterization, and therapeutic efficacy,” The International Journal of Nanomedicine, vol. 7, pp. 49–60, 2012. View at Google Scholar
  6. T. M. Allen and C. Hansen, “Pharmacokinetics of stealth versus conventional liposomes: effect of dose,” Biochimica et Biophysica Acta—Biomembranes, vol. 1068, no. 2, pp. 133–141, 1991. View at Publisher · View at Google Scholar · View at Scopus
  7. T. M. Allen, C. B. Hansen, and D. E. L. de Menezes, “Pharmacokinetics of long-circulating liposomes,” Advanced Drug Delivery Reviews, vol. 16, no. 2-3, pp. 267–284, 1995. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Helbok, C. Decristoforo, G. Dobrozemsky et al., “Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals,” Journal of Liposome Research, vol. 20, no. 3, pp. 219–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. W. T. Phillips, B. A. Goins, and A. Bao, “Radioactive liposomes,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, vol. 1, no. 1, pp. 69–83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Mitsuaki, Y. Hirohumi, C. Chia-Wun et al., “Lactose-carrying polystyrene as a drug carrier: investigation of body distributions to parenchymal liver cells using 125I-labelled lactose-carrying polystyrene,” Journal of Controlled Release, vol. 28, no. 1–3, pp. 223–233, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. H. M. Redhead, S. S. Davis, and L. Illum, “Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation,” Journal of Controlled Release, vol. 70, no. 3, pp. 353–363, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Van Der Geest, P. Laverman, D. Gerrits et al., “Comparison of three remote radiolabelling methods for long-circulating liposomes,” Journal of Controlled Release, vol. 220, pp. 239–244, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. N. O. Hodgins, J. T. Wang, A. C. Parente-Pereira, M. Liu, J. Maher, and K. T. Al-Jamal, “In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice,” Journal of Controlled Release, vol. 241, pp. 229–241, 2016. View at Google Scholar
  14. V. J. Richardson, K. Jeyasingh, and R. F. Jewkes, “Properties of [99mTc] technetium labelled liposomes in normal and tumour bearing rats,” Biochemical Society Transactions, vol. 5, no. 1, pp. 290-291, 1977. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Deliconstantinos, G. Ramantanis, and D. K. Todorou, “Interaction of 99mTc-labeled liposomes with walker tumour cells in vitro. Liposome-mediated introduction of thaliblastine into resistant walker tumour cells,” General Pharmacology, vol. 14, no. 4, pp. 407–411, 1983. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Oku, Y. Namba, A. Takeda, and S. Okada, “Tumor imaging with technetium-99m-DTPA encapsulated in RES-avoiding liposomes,” Nuclear Medicine and Biology, vol. 20, no. 4, pp. 407–412, 1993. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Goto, H. Kubo, and S. Okada, “Liposomes prepared from synthetic amphiphiles: I: their technetium labeling and stability,” Chemical and Pharmaceutical Bulletin, vol. 37, no. 5, pp. 1351–1354, 1989. View at Publisher · View at Google Scholar · View at Scopus
  18. Q. F. Ahkong and C. Tilcock, “Attachment of 99mTc to lipid vesicles containing the lipophilic chelate dipalmitoylphosphatidylethanolamine-DTTA,” International Journal of Radiation Applications and Instrumentation., vol. 19, no. 8, pp. 831–840, 1992. View at Publisher · View at Google Scholar · View at Scopus
  19. W. T. Phillips, A. S. Rudolph, B. Goins, J. H. Timmons, R. Klipper, and R. Blumhardt, “A simple method for producing a technetium-99m-labeled liposome which is stable in vivo,” International Journal of Radiation Applications and Instrumentation, vol. 19, no. 5, pp. 539–547, 1992. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Laverman, E. T. M. Dams, W. J. Oyen, and G. Storm, “A novel method to label liposomes with 99mTc by the hydrazino nicotinyl derivative,” Journal of Nuclear Medicine, vol. 40, pp. 192–197, 1999. View at Google Scholar
  21. C. Decristoforo and S. J. Mather, “99m-technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution,” Nuclear Medicine and Biology, vol. 26, no. 4, pp. 389–396, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. M. S. Rosenthal, J. Cullom, W. Hawkins, S. C. Moore, B. M. W. Tsui, and M. Yester, “Quantitative SPECT imaging: a review and recommendations by the focus committee of the society of nuclear medicine computer and instrumentation council,” Journal of Nuclear Medicine, vol. 36, pp. 1489–1513, 1995. View at Google Scholar
  23. M. Ljungberg, “Quantitative SPECT imaging,” in Basic Sciences of Nuclear Medicine, pp. 285–309, Springer, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Schibli and A. P. Schubiger, “Current use and future potential of organometallic radiopharmaceuticals,” European Journal of Nuclear Medicine, vol. 29, no. 11, pp. 1529–1542, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. R. C. King, M. B.-U. Surfraz, S. C. G. Biagini, P. J. Blower, and S. J. Mather, “How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies,” Dalton Transactions, no. 43, pp. 4998–5007, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. R. Dilworth and S. J. Parrott, “The biomedical chemistry of technetium and rhenium,” Chemical Society Reviews, vol. 27, no. 1, pp. 43–55, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Alberto, R. Schibli, A. Egli, A. P. Schubiger, U. Abram, and T. A. Kaden, “A novel organometallic aqua complex of technetium for the labeling of biomolecules: synthesis of [99mTc(OH2)3(CO)3]+ from [99mTcO4]- in aqueous solution and its reaction with a bifunctional ligand,” Journal of the American Chemical Society, vol. 120, no. 31, pp. 7987-7988, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Egli, R. Alberto, L. Tannahill, and R. Schibli, “Organometallic 99mTc-Aquaion labels peptide to an unprecedented high specific activity,” Journal of Nuclear Medicine, vol. 40, pp. 1913–1917, 1999. View at Google Scholar
  29. M.-L. Biechlin, A. Du Moulinet D'Hardemare, M. Fraysse, F.-N. Gilly, and A. Bonmartin, “Improvement in radiolabelling proteins with the 99mTc- tricarbonyl-core [99mTc(CO)3]+, by thiol-derivatization with iminothiolane: application to γ-globulins and annexin V,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 48, no. 12, pp. 873–885, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. M.-L. Biechlin, A. Bonmartin, F.-N. Gilly, M. Fraysse, and A. du Moulinet d'Hardemare, “Radiolabeling of annexin A5 with 99mTc: comparison of HYNIC-Tc vs. iminothiolane-Tc-tricarbonyl conjugates,” Nuclear Medicine and Biology, vol. 35, no. 6, pp. 679–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Carpenet, A. Cuvillier, J. Monteil, I. Quelven, and S. Muyldermans, “Anti-CD20 Immunoglobulin G Radiolabeling with a 99mTc-tricarbonyl core: in vitro and in vivo evaluations,” PLoS ONE, vol. 10, no. 10, Article ID e0139835, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Glück, R. Mischler, S. Brantschen, M. Just, B. Althaus, and S. J. Cryz Jr., “Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A,” Journal of Clinical Investigation, vol. 90, no. 6, pp. 2491–2495, 1992. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Loutan, P. Bovier, B. Althaus, and R. Glück, “Inactivated virosome hepatitis A vaccine,” The Lancet, vol. 343, no. 8893, pp. 322–324, 1994. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Herzog, K. Hartmann, V. Künzi et al., “Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine,” Vaccine, vol. 27, no. 33, pp. 4381–4387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Usonis, V. Bakasénas, R. Valentelis, G. Katiliene, D. Vidzeniene, and C. Herzog, “Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®),” Vaccine, vol. 21, no. 31, pp. 4588–4592, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. R. A. Schwendener, “Liposomes as vaccine delivery systems: a review of the recent advances,” Therapeutic Advances in Vaccines, vol. 2, pp. 159–182, 2014. View at Google Scholar
  37. K. Sou, T. Endo, S. Takeoka, and E. Tsuchida, “Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles,” Bioconjugate Chemistry, vol. 11, no. 3, pp. 372–379, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. J.-L. Rigaud, B. Pitard, and D. Levy, “Reconstitution of membrane proteins into liposomes: application to energy-transducing membrane proteins,” Biochimica et Biophysica Acta (BBA)-Bioenergetics, vol. 1231, no. 3, pp. 223–246, 1995. View at Publisher · View at Google Scholar · View at Scopus